Arcturus Therapeutics, Inc.
10628 Science Center Drive
Suite 250
San Diego
CA
92121
United States
38 articles with Arcturus Therapeutics, Inc.
-
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
9/8/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: TIDES: Oligonucleotide and Peptide Therapeutics scientific conference
-
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
8/18/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it has executed the definitive supply agreement provided for in the previously announced binding term sheet agreement with the Israeli Ministry of Health,
-
Clinical Catch-Up: August 10-14
8/17/2020
It was a very busy week for clinical trial updates. Here’s a look. -
Arcturus Therapeutics Announces that it has Initiated Dosing of its COVID-19 STARR™ mRNA Vaccine Candidate, LUNAR-COV19 (ARCT-021) in a Phase 1/2 study
8/11/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that all subjects in the first cohort have been dosed in the Phase 1/2 clinical study with its ARCT-021 investigational vaccine for COVID-19.
-
Arcturus Therapeutics Announces Second Quarter 2020 Financial Results and Provides a Corporate Update
8/10/2020
COVID-19 STARR™ mRNA vaccine candidate, ARCT-021 (LUNAR-COV19) has initiated Phase 1/2 clinical study with Duke-NUS Medical School; Dosing anticipated imminently, initial data expected Q4
-
Arcturus Therapeutics Appoints Lance Kurata as Chief Legal OfficerNationally recognized leader in corporate life sciences transactions
8/6/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced the appointment of Lance Kurata as Chief Legal Officer, starting August 10, 2020. Mr. Kurata joins Arcturus from Mintz, where he was a partner in the Corporate Group an
-
Arcturus Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - July 31, 2020
7/31/2020
Arcturus Therapeutics Holdings Inc. announced the closing on July 31, 2020 of its previously announced underwritten public offering of 3,753,773 shares of its common stock at a public offering price of $53.00 per share, which included the exercise in full by the underwriters of their option to purchase up to an additional 489,622 shares of common stock at the public offering price, less underwriting discounts and commissions.
-
Arcturus Therapeutics Announces Pricing of $173.0 Million Public Offering of Common Stock
7/29/2020
Arcturus Therapeutics Holdings Inc. announced the pricing of an underwritten public offering of 3,264,151 shares of its common stock at a public offering price of $53.00 per share.
-
Arcturus Therapeutics Announces Proposed Public Offering of Common Stock - July 28, 2020
7/28/2020
Arcturus Therapeutics Holdings Inc., a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
-
Arcturus Therapeutics Announces Agreement with Israeli Ministry of Health to Supply COVID-19 Vaccine Candidate, LUNAR-COV19
7/23/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced a binding term sheet with the Israeli Ministry of Health to supply the Company’s COVID-19 vaccine candidate, LUNAR-COV19
-
Arcturus Therapeutics & Duke-NUS Received Approval to Proceed with Phase 1/2 Clinical Trial for COVID-19 Vaccine Candidate, LUNAR-COV19
7/21/2020
Human dosing of LUNAR-COV19 expected soon Differentiated STARR™ mRNA vaccine expected to produce humoral and cellular immunity at very low doses New preclinical data demonstrates neutralizing antibody titers continue to increase for 50 days after a single administration
-
Arcturus Therapeutics Announces the Formation of its Vaccine Platform Scientific Advisory Board
7/1/2020
Renowned experts in virology, infectious disease, vaccine development and public health to support Arcturus’ COVID-19 vaccine program, LUNAR-COV19 Company remains on track to begin clinical trial for COVID-19 vaccine this summer SAN DIEGO, July 01, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for ra
-
Arcturus Therapeutics to be Added to Russell 2000® Index
6/29/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will be added to the Russell 2000 ® Index, as part of the 2020 Russell indexes reconstitution. The addition will be effective after the U.S. market opens on June 29, 2020 as part of th
-
Clinical Catch-Up: May 31-June 5
6/8/2020
As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look. -
Arcturus Therapeutics Announces First Healthy Volunteer Dosed in Phase 1 Study of ARCT-810 for Ornithine Transcarbamylase (OTC) Deficiency
6/5/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it has dosed the first healthy volunteer in a Phase 1 study with ARCT-810, the Company’s messenger RNA (mRNA)-based therapeutic candidate for Ornithine Transcarbamylase (OTC) deficiency.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.
-
Arcturus Reports Additional Supportive Preclinical Data for its COVID-19 Vaccine Candidate (LUNAR-COV19)
5/8/2020
New data provides evidence of adaptive cellular (CD8+ cells) and balanced (Th1/Th2) immune responses STARR™ mRNA elicits anti-spike protein antibodies (IgG), higher than conventional mRNA at all doses SAN DIEGO, May 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, tod
-
Arcturus Therapeutics Announces First Quarter 2020 Financial Results and Provides a Corporate Update
5/7/2020
Important progress advancing COVID-19 STARR™ mRNA vaccine candidate (LUNAR-COV19); New preclinical data demonstrate robust immunogenicitywith a single, low dose
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 4, 2020.
-
Arcturus Therapeutics to Report First Quarter 2020 Financial Results and Provide a Corporate Update on May 7, 2020
5/4/2020
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will release its financial results for the quarter ended March 31, 2020 after the market close on May 7 and will also provide a corporate overview and financial results by hosting a conference call